Mural Oncology appoints George Golumbeski, Ph.D., as independent director

Mural Oncology plc

Appointed July 30, 2024; term expires at 2025 annual general meeting.
Initial option grant of 15,334 shares at $3.38 strike, vesting quarterly over three years.
Annual cash compensation of $40,000 plus annual equity grants under non-employee director program.
Board determined Dr. Golumbeski is independent under Nasdaq rules.
No family relationships or transactions requiring disclosure; standard indemnification agreements.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

George Golumbeski, Ph.D.

director

Mural Oncology plc

Effective: 2024-07-30
Filed: July 31, 2024, 7:59 PM ET

On July 30, 2024, the Board of Directors (the “Board”) of Mural Oncology plc (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, appointed George Golumbeski, Ph.D., as a director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

George Golumbeski, Ph.D. was appointed as director at Mural Oncology plc.

Action: appointed
Role: director

Exact text from the filing

On July 30, 2024, the Board of Directors (the “Board”) of Mural Oncology plc (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, appointed George Golumbeski, Ph.D., as a director

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-189472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.